Tianjin Xinchen Taifeier Pharmaceutical Technology

Tianjin Xinchen Taifeier Pharmaceutical Technology is a specialized biopharmaceutical research entity based in Tianjin, China, operating as a subsidiary of Jiangsu Xinchen Pharmaceutical within the Jiangsu Hengrui Pharmaceuticals group. The company focuses on the discovery and clinical development of novel small molecule therapeutics for perioperative care, specifically targeting the anesthesia and analgesia markets. Its pipeline includes innovative candidates such as XCTF-101, a long-acting local anesthetic, and XCTF-201, a sedative agent designed for surgical and intensive care settings. By leveraging the extensive R&D and commercialization infrastructure of the Hengrui ecosystem, Tianjin Xinchen Taifeier plays a critical role in advancing next-generation pain management solutions in China.